Ceftobiprole: An Extended-Spectrum Anti–Methicillin-Resistant Staphylococcus aureus Cephalosporin

Shawn D Anderson, PharmD; John G Gums, PharmD, FCCP


The Annals of Pharmacotherapy. 2008;42(6):806-816. 

In This Article

Dosing and Administration

Based on pharmacokinetic and pharmacodynamic data, Monte Carlo simulations, and Phase 3 clinical trials, the predicted FDA-approved dose of ceftobiprole medocaril for suspected or documented gram-postive cSSSIs will be 500mg intravenously every 12 hours (1-h infusion) for 7–14 days. Predicted approved dosing if gram-negative pathogens are suspected or isolated, such as in a diabetic foot infection, may be 500mg intravenously every 8 hours (2-h infusion) for 7–14 days. The latter dose is predicted if current Phase 3 clinical trials show effectiveness of ceftobiprole in community-acquired pneumonia, hospital-acquired pneumonia, and chemotherapy-induced fever and neutropenia. As ceftobiprole is predominantly eliminated unchanged in the urine at a rate comparable to the normal glomerular filtration rate, reduced doses in renal impairment are required. Proposed renal dose adjustments are based on Cockcroft-Gault calculations of estimated Cl cr using actual body weight. All proposed dose adjustments are administered as 2-hour infusions: mild renal impairment (50–80mL/min) is 500mg every 8 hours, moderate (30–49mL/min) is 500mg every 12 hours, and severe (<30mL/min) is 250mg every 12 hours.[35] These recommendations have not been prospectively evaluated in clinical trials.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.